Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-18.

J Alastair Gracie1, Susan E Robertson, Iain B McInnes

  • 1Centre for Rheumatic Diseases, University of Glasgow, 10 Alexandra Parade, Glasgow G31 2ER, Scotland, UK.

Journal of Leukocyte Biology
|January 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Rheumatology and therapy·2026
Same author

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

Rheumatology (Oxford, England)·2026
Same author

Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.

Rheumatology and therapy·2026

Interleukin-18 (IL-18) is a key regulator of immune responses, found in chronic inflammation, autoimmune diseases, cancers, and infections. This review details IL-18 biology and its role in human diseases like autoimmunity and infection.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cytokine Research

Background:

  • Interleukin-18 (IL-18) is a cytokine involved in immune regulation.
  • IL-18 is implicated in various conditions including autoimmune diseases, cancers, and infections.
  • IL-18 was initially identified as an interferon-gamma (IFN-gamma)-inducing factor.

Purpose of the Study:

  • To review the fundamental biology of Interleukin-18 (IL-18).
  • To examine the effector and regulatory functions of IL-18 in human diseases.
  • To explore IL-18's role in autoimmunity and infectious diseases.

Main Methods:

  • Literature review of IL-18's biological functions and disease associations.
  • Analysis of IL-18's molecular characteristics, including precursor and mature protein structures.

Related Experiment Videos

  • Comparison of murine and human IL-18 sequences.

    • Main Results:

    • IL-18 is a member of the IL-1 cytokine superfamily and a critical regulator of innate and acquired immunity.
    • IL-18 expression is observed in chronic inflammatory sites, autoimmune conditions, cancers, and infectious diseases.
    • Both murine and human IL-18 share significant sequence homology and possess unusual N-terminal leader sequences.

    Conclusions:

    • Interleukin-18 (IL-18) plays a significant role in immune responses and various human diseases.
    • Understanding IL-18's biology is crucial for investigating its therapeutic potential in autoimmunity and infection.
    • Further research into IL-18 mechanisms can inform disease management strategies.